In:
Angiology, SAGE Publications, Vol. 41, No. 5 ( 1990-05), p. 377-381
Abstract:
The effects of the angiotensin-converting enzyme inhibitor captopril on blood pressure, heart rate, plasma prolactin, and renin activity were examined in a single-blind, placebo-controlled trial on 30 patients with essential hypertension (15 given drug, 15 placebo). Captopril, 25 mg administered orally, reduced the blood pressure and increased the plasma renin activity. Captopril decreased mean plasma prolactin from 17.5±1.4 ng/mL to 9.1±1.0 ng/mL (p 〈 0.001). Significant correlation was found between captopril-induced change from control values of plasma prolactin (Δplasma prolactin) vs Δplasma renin activity (r = -0.688, p 〈 0.001). These results suggest that acute administration of captopril was accompanied by a reduction in plasma prolactin and that this reduction may be of clinical significance during therapy of hypertension.
Type of Medium:
Online Resource
ISSN:
0003-3197
,
1940-1574
DOI:
10.1177/000331979004100504
Language:
English
Publisher:
SAGE Publications
Publication Date:
1990
detail.hit.zdb_id:
2065911-8
Bookmarklink